NLY03

About Neuraly

Neuraly is a private, clinical-stage biotech pioneering novel therapeutics for neurodegenerative diseases. Its lead asset, NLY01, is a long-acting GLP-1R agonist currently in Phase 2 trials for both Parkinson's and Alzheimer's disease, with a mechanism centered on modulating neuroinflammation by targeting microglia and astrocytes. The company's pipeline also includes earlier-stage, orally active small molecules (NLY02, NLY03) targeting similar pathways, positioning Neuraly in the competitive but high-potential neurotherapeutics space. Its strategy leverages a well-known drug class (GLP-1 agonists) for new CNS indications to potentially derisk and accelerate development.

Therapeutic Areas